Gatehouse Bio

Executive Summary

Gatehouse Bio is a private biotechnology company headquartered in Cambridge, MA, founded in 2021 with a mission to decode the RNA code underlying all diseases. The company’s proprietary Code-Breaker™ platform leverages artificial intelligence to map the landscape of small RNAs (sRNAs) and design precision oligonucleotide therapeutics guided by biomarkers. By integrating AI-driven discovery with targeted therapeutic design, Gatehouse Bio aims to address diseases at the RNA level, potentially unlocking novel treatment avenues for currently intractable conditions. The platform’s ability to identify disease-specific sRNA signatures and translate them into oligonucleotide candidates positions the company at the forefront of RNA-based precision medicine. As a private, early-stage entity, Gatehouse Bio has not disclosed specific financials or lead program details, but its focus on sRNA biology and AI-driven drug development aligns with industry trends toward RNA therapeutics and digital biomarker integration. The company is expected to advance its lead programs toward preclinical proof-of-concept, with potential catalysts including the release of in vivo data, strategic partnerships with larger biopharma firms, and additional financing rounds to support IND-enabling studies. Given its novel approach and the growing interest in RNA-targeted therapies, Gatehouse Bio represents a compelling, albeit early-stage, opportunity in the precision medicine landscape.

Upcoming Catalysts (preview)

• H1 2027Preclinical in vivo data for lead sRNA-targeted program60% success
• H2 2026Partnership or collaboration with a large pharma or diagnostics company40% success
• Q4 2026Series A or B financing round70% success